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Transplantation
Congenital dyserythropoietic anemias (CDA) are a
group of heterogeneous disorders characterized by
hyporegenerative anemia and ineffective erythropoiesis,
with related reticulocytopenia, and iron overload.1
Specific morphological aspects of late erythroblasts in the
bone marrow form the most important, albeit non-specif-
ic, feature of the disease. Morphology has always been
the most important tool for diagnosis and is still used to
classify the disease into three classical forms and
variants.2 Nonetheless, in the last few years, mutations of
six specific genes related to the regulation of DNA and
cell division have been identified as being causative.3-5
Patients with CDA usually show anemia, jaundice,
splenomegaly, ineffective erythropoiesis and the typical
marrow features. Somatic abnormalities involving fingers
and nails can be part of the clinical features.
The management of the disease is generally limited to
blood transfusion and iron chelation. Interferon-α treat-
ment has also been successfully used in patients with
CDA type I,6,7 whereas splenectomy has been proved to
reduce the number of transfusions in CDA II.8
Overall, the prognosis of CDA patients is good;2 how-
ever, stem cell transplantation (SCT) represents the only
curative option for this disease. Some reports have
shown its efficacy, but data from the literature are scarce
and limited to a very small number of patients, mostly
transplanted from sibling donors.9-16 
In this retrospective study, we describe the outcome of
SCT in a large cohort of patients with CDA. The study
was conducted on behalf of the Severe Aplastic Anemia
Working Party (SAAWP) of the European Society for
Bone and Marrow Transplantation (EBMT) and relied on
data from patients affected with CDA who underwent
SCT and were registered in the EBMT Database. Clinical
information on the disease was collected by a question-
naire distributed to participating centers and the details
on transplant procedures were obtained by analyzing the
database. 
Engraftment was defined as neutrophil count >0.5 x
109/L for at least three consecutive days. Primary graft
failure was defined as neutrophil count never reaching
>0.5x109/L and secondary graft failure was defined as a
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Figure 1. Outcome of patients
with congenital dyserythropoiet-
ic anemias (CDA)  undergoing
stem cell transplantation (SCT).
(A) Overall survival (OS). (B)
Event-free survival. (C) OS
according to donor type. (D) OS
according to iron overload. (E)
Graft failure incidence according
to donor type. (F) Graft failure
incidence according to iron over-
load. 
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C D
E F
P=0.007
P=0.055 P=0.024
P=0.05
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Table 1. Patients’ characteristics and transplant features.
Patients’characteristics                                N=39                    SCT from sibling             SCT from MUD                           36 months OS
CDA sub-types       
type I                                                                       10 (26%)                                    8                                            2                                                         80%
type II                                                                      13 (33%)                                    5                                            8                                                         61%
type IV                                                                      1 (3%)                                      0                                            1                                                            
xltda (gata-1)                                                          1 (3%)                                      0                                            1
Missing                                                                   14 (35%)                                                                                   
Molecular mutation
SEC23B                                                                   6 (15%)                                     2                                            4
GATA-1                                                                      2 (5%)                                      1                                            1
CDAN1                                                                      1 (3%)                                      1                                            0
No mutation                                                         24 (62%)                                   14                                          10                                                           
Missing                                                                   6 (15%)                                     4                                            2
Somatic abnormalities                                       8/39 (20%) 
Skeletal                                                                           4                                            2                                            2                                                            
Skin                                                                                1                                            0                                            1                                                            
Neurological                                                                3                                            1                                            2                                                            
Retina                                                                            0                                            0                                            0
Dysmorphic face                                                         1                                           1                                            0                                                            
Macrocephaly                                                             1                                           1                                            0                                                           
Pre-transplant treatment                                    20 (51%)                                     
Splenectomy                                                           2 (5%)                                      0                                            2                                                            
Chelation treatment                                           13 (33%)                                    7                                            6                                                            
IFN                                                                           5 (13%)                                     1                                            4                                                            
Clinical manifestation at SCT
Hepatomegaly                                                      15 (38%)                                    9                                            6                                                         77%
Jaundice                                                                 9 (23%)                                     6                                            3                                                         41%
Splenomegaly                                                       18 (46%)                                   12                                           6                                                         68%
Iron overload                                                       17 (43%)                                    8                                            9                                                         51%
Age at HSCT, years (median, range)               5.1 (0.9-38)                            4(1-38)                              7(0.9-31)                                                     
Time from diagnosis to SCT,                          34.8 (2.4-377)                        23(2-177)                            55(2-377)
months (median, range)                                                                                           
Performance status at HSCT 
(Lansky or Karnofsky)
<90                                                                          5 (13%)                                     3                                            2
90-100                                                                     28 (71%)                                   16                                          12
Missing                                                                   6 (15%)                                                                                                                                                 
Year of SCT                                                                     
Before 2010                                                          18 (46%)                                   11                                           7                                                         65%
After 2010                                                             21  (54%)                                   11                                          10                                                        79%
Donor type
Identical sibling                                                   20 (51%)                                                                                                                                             90%
Unrelated donor                                                  17 (44%)                                                                                                                                             45%
Other relative                                                       2    (5%)                                                                                                                                                 
HLA match
10/10                                                                              12                                    4 (29%)                               7 (47%)                                                  66%
<10/10                                                                          19                                   10 (71%)                                    8                                                         58%
Missing                                                                         8                                             
Stem cell source
Bone marrow                                                       30 (76%)                                   18                                          12
Peripheral blood                                                  7  (18%)                                     3                                            4
Cord blood                                                             2   (5%)                                     1                                            1                                                            Continued on next page
decrease in neutrophil count to a lower level after initial
engraftment. Overall survival (OS) and event-free sur-
vival (EFS), defined as survival without rejection, graft
loss or a second transplant, were calculated using the
Kaplan-Meier product limit estimation method; differ-
ences in subgroups were assessed by the Log rank test.
Median follow up was estimated using the reverse
Kaplan-Meier method. Cumulative incidences of grade II-
IV acute graft-versus-host disease (aGvHD), of
limited/extensive chronic GvHD (cGvHD), and of graft
failure were analyzed separately in a competing risks
framework, and subgroup differences were assessed by
Gray test. Competing events for graft failure,
acute/chronic GvHD, include second transplant, relapse
and death. All estimates were reported with a correspon-
ding 95% confidence interval;  P<0.05 was considered
significant. Iron overload was defined as ferritin serum
level >1000 mg/dL or as the presence of pathological liver
iron concentration by magnetic resonance imaging
(MRI). 
Between 1996 and 2016, 39 patients (22 males), with a
median age of 5.1 years (range, 0.9-38.2) underwent SCT
following a conditioning regimen that was myeloablative
in all but one case. SCT was performed because of trans-
fusion dependency alone (n=34) or associated with iron
overload (n=5). Patients’ clinical characteristics are
shown in Table 1. Only one patient in this cohort has
been previously reported.10
All patients were engrafted. The 3-year incidence of
secondary graft failure was 12% (1-23%). Median days to
neutrophil and platelet recovery were 21 (range, 10-75)
and 34 (range, 16-399), respectively. Conditioning regi-
mens and transplant features are shown in Table 1.
Median follow up was 44 months (range, 13-71, with 13
transplants performed in the last two years of the study
period). OS and EFS at 36 months were 71% (55-87%)
and 45% (45-63%), respectively (Figure 1A and B). Ten
patients died; death was due to GvHD (n=6), infection
(n=3), or multi-organ failure (n=1). Patients who were
transplanted from unrelated donor (UD) had an inferior
outcome compared with those engrafted from matched
sibling donors (MSD) [OS 51% (range, 26-76%) vs. 92%
(range, 76-100%); P=0.05]. OS of patients with iron over-
load was significantly worse [45% (range, 18-2%) vs.
90% (range, 76-100%) P=0.007] compared with those
transplanted without (Figure 1C and D). There was no
difference in survival between patients transplanted
before and after 2010, or between patients conditioned
with or without fludarabine. The incidence of graft fail-
ure in patients transplanted with and without iron over-
load was 17% (range, 0-38%) and 6% (range, 0-17%),
respectively (P=0.382). Graft failure was 6% (range, 0-
17%) and 16% (range, 0-32%) in patients transplanted
from MSD and UD, respectively (P=0.497). Of note, this
probability, due to competitive causes, was significantly
higher in patients transplanted with versus without iron
overload (59% vs.17%; P=0.024) and from a UD versus a
MSD, respectively (55% vs. 31%; P=0.05) (Figure 1E and
F). A trend towards a higher incidence of grade II-IV
aGvHD was also seen in patients transplanted from a UD
haematologica 2019; 104:e337
LETTERS TO THE EDITOR
Busulfan-based conditioning                              28 (72%)                                   18                                          10                                                           
Bu-Cy                                                                           10                                         10                                           0                                                            
Bu-Cy-ATG                                                                    9                                            6                                            3
Bu-Flu-ATG                                                                  3                                            2                                            1
Bu-Flu-TT                                                                     1                                            0                                            1
Bu-Flu-TT                                                                     1                                            0                                            1                                                            
Bu-Flu-Cy-ATG                                                            2                                            0                                            2
Bu-Flu-LPAM -ATG                                                     1                                            0                                            1                                                            
Bu-Cy-LPAM-ATG                                                       1                                           0                                           1                                                            
Treosulfan-based conditioning                           8 (20%)                                     1                                            7
Treo-Flu-TT                                                                 2                                            0                                            2
Treo-Flu-TT-ATG                                                        4                                            0                                            4
Treo-Flu-LPAM-ATG                                                  1                                           1                                            0
Treo-Cy -ATG                                                               1                                            0                                            1                                                            
Other conditioning                                                 3 (8%)
Cy                                                                                   1                                            2                                            0
Cy-ATG                                                                           1                                            1                                            0
Missing                                                                        1      
Secondary graft failure                                               8                                           4                                            4
Acute GvHD, grade III-IV (100 days)                       11                                          2                                            9
Chronic GvHD (36 months)                                                                                     5                                            2
Limited/Extensive                                                      7
Death                                                                              10                                          2                                            8
Follow up, median months (range)               44 (13 – 71)                                                                                
CDA: congenital dyserithropoietic anemia; SCT: stem cell transplantation; MUD: marrow unrelated donor; IFN: interferon; HLA: human leukocite antigen; Bu: busulfan; 
Flu: fludarabine; TT: thiotepa; Cy: cyclophosfamide; ATG: anti-thymocyte globulin; L-PAM: melphalan; GvHD: graft-versus-host disease. OS: overall survival.
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(59% vs. 25%; P=0.06) and with iron overload (53% vs.
25%; P=0.1), as compared to those engrafted from MSD
and with no iron overload, respectively. Severe (Grade
III-IV) aGvHD incidence was 29%, and was significantly
higher (P=0.005) in UD (53%) than in MSD transplants
(10%). 
To the best of our knowledge, this is the largest report-
ed cohort of patients transplanted for CDA. Previous
publications have been anecdotal experiences including a
total of thirteen children, composed of CDA type I,9 type
II,10-13 and type III,16 transplanted from sibling donors in
all cases except for three patients who were transplanted
from a UD.11,12,16 Of particular note, our study, which
included 44% of patients transplanted from a UD,
showed that donor type still affects the outcome since
MSD SCT patients  have superior OS and engraftment.
Another factor affecting the outcome of our cohort was
iron overload, which is an intrinsic feature of patients
with CDA due to hepcidin downregulation and ineffec-
tive erythropoiesis. We also found an association
between iron overload and GvHD that might become
fully significant if a larger number of patients was avail-
able. Previous reports on thalassemia17,18 showed that tis-
sue damage secondary to iron accumulation may
enhance the risk of transplant-related toxicity and predis-
pose patients to a higher incidence of aGvHD. This out-
lines the importance of a pre-transplant definition of the
risk the patients may incur, which generated a dramatic
improvement in the outcome in the case of thalassemia
patients (Pesaro risk classes).17 The lack of such a pre-SCT
selection in CDA patients might explain their worse out-
come compared with other transfusion-dependent,
hemolytic anemias like the thalassemias; indeed, the bet-
ter outcome of CDA patients transplanted without iron
overload seems to support this hypothesis. Amongst the
risk factors, iron overload in CDA candidates for SCT
needs to be carefully evaluated and reduced with effec-
tive chelation. 
Graft rejection of this CDA cohort was comparable to
that seen in thalassemia patients19 and was negatively
affected by donor type (worse with UD) and iron over-
load. This points to the need for careful evaluation of the
choice of donor type in the decision-making process. 
Most patients were conditioned with myeloablative
regimens including busulfan/treosulfan. In the limited
number of cases included in this study, no difference was
noted compared to patients who, in addition, received
fludarabine or cyclophosphamide. Of note, the only
patients of our cohort who received a non-myeloablative
conditioning regimen had a successful outcome, as did
the only previously reported CDA subject,16 who was
conditioned with fludarabine-cyclophosphamide and 
a-day course of total body irradiation. This raises the
issue of the appropriateness of reduced-intensity condi-
tioning in CDA. Unfortunately, we could not address this
aspect in this study due to the lack of available data, but
it might be worth investigating in future analyses.
In conclusion, despite the lower overall outcome com-
pared to previous reports on thalassemia patients, SCT
may represent an alternative therapeutic option in CDA,
with outcomes appearing to be superior in patients trans-
planted from MSD and without iron overload. Indeed,
iron overload is an important factor that needs to be con-
trolled and eventually treated before transplant. In this
respect, CDA patients might benefit from pre-SCT risk
assessment, e.g. like the Pesaro criteria, which may have
a favorable impact on the overall outcome. The high inci-
dence of graft failure and aGvHD, and the lower overall
survival observed in patients transplanted from UD,
should be taken into consideration and discussed with
parents if a familial donor is not available. 
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